What is the current and future status of conventional amphotericin B?

International Journal of Antimicrobial Agents

Volumn 27, Issue SUPPL. 1, 2006, Pages 12-16

  Kleinberg, Michael ^a  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

Amphotericin B deoxycholate; Amphotericin B lipid complex; Cost; Invasive aspergillosis; Liposomal amphotericin B; Nephrotoxicity; Renal failure

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; GOLD STANDARD; HOSPITALIZATION; HUMAN; MORTALITY; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CHEMISTRY, PHARMACEUTICAL; COLLOIDS; DEOXYCHOLIC ACID; DRUG COMBINATIONS; HUMANS; LIPOSOMES; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; TREATMENT OUTCOME;

EID: 33646836577     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.03.013     Document Type: Article

References (27)

1. Walsh T.J., Melcher G.P., Rinaldi M.G., et al. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol 28 (1990) 1616-1622
2. Walsh M., White L., Atkinson K., and Enno A. Fungal Pseudoallescheria boydii lung infiltrates unresponsive to amphotericin B in leukaemic patients. Aust N Z J Med 22 (1992) 265-268
3. Wingard J.R., Kubilis P., Lee L., et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 29 (1999) 1402-1407
4. Harbarth S., Burke J.P., Lloyd J.F., Evans R.S., Pestotnik S.L., and Samore M.H. Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. Clin Infect Dis 35 (2002) 120-127
5. Walsh T.J., Hiemenz J.W., Seibel N.L., et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 26 (1998) 1383-1396
6. Anaissie E.J., White M.H., Uzun O., et al. Amphotericin B lipid complex (ABLC) vs amphotericin B (AMB) for treatment of haematogenous and invasive candidiasis: a prospective, randomized, multicenter trial. Proceedings of the 35th interscience conference on antimicrobial agents and chemotherapy. San Francisco, September 17-20 (1995) Abstr LM21
7. Alexander B.D., and Wingard J.R. Study of renal safety in amphotericin B lipid complex-treated patients. Clin Infect Dis 40 Suppl. 6 (2005) S414-S421
8. Walsh T.J., Finberg R.W., Arndt C., et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 340 (1999) 764-771
9. Walsh T.J., Pappas P., Winston D.J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and spersistent fever. N Engl J Med 346 (2002) 225-234
10. Walsh T.J., Teppler H., Donowitz G.R., et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351 (2004) 1391-1402
11. Bowden R., Chandrasekar P., White M.H., et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 35 (2002) 359-366
12. Cagnoni P.J., Walsh T.J., Prendergast M.M., et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 18 (2000) 2476-2483
13. Rex J.H., Walsh T.J., Nettleman M., et al. Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis 33 (2001) 95-106
14. White M.H., Anaissie E.J., Kusne S., et al. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 24 (1997) 635-642
15. Patterson T.F., Kirkpatrick W.R., White M., et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 79 (2000) 250-260
16. Denning D.W. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 23 (1996) 608-615
17. Chandrasekar P.H., and Ito J.I. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 40 Suppl. 6 (2005) S392-S400
18. Walsh T.J., Goodman J.L., Pappas P., et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 45 (2001) 3487-3496
19. Hooshmand-Rad R., Reed M.D., Chu A., et al. Retrospective study of the renal effects of amphotericin B lipid complex when used at higher-then-recommended dosages and longer durations compared with lower dosages and shorter durations in patients with systemic fungal infections. Clin Ther 26 (2004) 1652-1662
20. Bates D.W., Su L., Yu D.T., et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 32 (2001) 686-693
21. Rex J.H., Bennett J.E., Sugar A.M., et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Canadidemia Study Group and the National Institute. N Engl J Med 331 (1994) 1325-1330
22. Mora-Duarte J., Betts R., Rotstein C., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347 (2002) 2020-2029
23. Kullberg B.J., Sobel J.D., Ruhnke M., et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366 (2005) 1435-1442
24. Pappas P.G., Rex J.H., Lee J., et al. A prospective, observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 37 (2003) 634-643
25. Ito J., and Hooshmand-Rad R. Treatment of Candida infections with amphotericin B lipid complex. Clin Infect Dis 40 Suppl. 6 (2005) S384-S391
26. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347 (2002) 408-415
27. Clark J.M., Whitney R.R., Olsen S.J., et al. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 35 (1991) 615-621